Related Experiment Videos
[Information regarding adverse drug effects and treatment indications ("package inserts") exemplified by cervistatin
Robert N Braun1, Max J Halhuber, Gerhart Hitzenberger
1Arbeitsgemeinschaft zur Erforschung-der Allgemeinmedizin, Lüt-zowgasse 6/3/21, A-1140 Wien.
Wiener Medizinische Wochenschrift (1946)
|March 28, 2003
Abstract:
A worldwide frequently applied HMG-CoA-reductase-inhibitor ("statin") recently has been withdrawn from the market. This obviously has been caused by serious adverse events. The question is whether the package inserts sufficiently inform about the risks. But, although they list up numerous side effects, they lack informations concerning the frequency of them, so the patients when reading the package inserts become confused. Thus they have to rely on their doctors choice regarding the danger outlined in the inserts. In that respect packing inserts could be improved.